Factor analysis of proton MR spectroscopic imaging data in HIV infection: Metabolite-derived factors help identify infection and dementia

Radiology

Volumn 254, Issue 2, 2010, Pages 577-586

  Mohamed, Mona A ^a   Lentz, Margaret R ^b   Lee, Vallent ^b   Halpern, Elkan F ^b   Sacktor, Ned ^a   Selnes, Ola ^a   Barker, Peter B ^a   Pomper, Martin G ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CHOLINE; CREATINE; MONOCYTE CHEMOTACTIC PROTEIN 1; N ACETYLASPARTIC ACID; PROTON; ASPARTIC ACID; DRUG DERIVATIVE; N-ACETYLASPARTATE;

ADULT; ARTICLE; BLOOD SAMPLING; CEREBROSPINAL FLUID ANALYSIS; CLINICAL FEATURE; COGNITIVE DEFECT; CONTROLLED STUDY; DEMENTIA; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFORMED CONSENT; MAJOR CLINICAL STUDY; MALE; MONOCYTE; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE; PATHOGENESIS; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; SERODIAGNOSIS; ANALYSIS OF VARIANCE; CASE CONTROL STUDY; CHI SQUARE DISTRIBUTION; FACTORIAL ANALYSIS; HIV ASSOCIATED DEMENTIA; METABOLISM; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY;

ADULT; AIDS DEMENTIA COMPLEX; ANALYSIS OF VARIANCE; ASPARTIC ACID; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; CHOLINE; CREATINE; FACTOR ANALYSIS, STATISTICAL; FEMALE; HIV INFECTIONS; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; NEUROPSYCHOLOGICAL TESTS;

EID: 77449118975     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.09081867     Document Type: Article

References (47)

1. Buckner CM, Luers AJ, Calderon TM, Eugenin EA, Berman JW. Neuroimmunity and the blood-brain barrier: molecular regulation of leukocyte transmigration and viral entry into the nervous system with a focus on neuroAIDS. J Neuroimmune Pharmacol 2006;1:160-181.
2. Chang L, Ernst T, Leonido-Yee M, Walot I, Singer E. Cerebral metabolite abnormalities correlate with clinical severity of HIV-1 cognitive motor complex. Neurology 1999;52:100-108.
3. Chang L, Lee PL, Yiannoutsos CT, et al. A multicenter in vivo proton-MRS study of HIV-associated dementia and its relationship to age. Neuroimage 2004;23:1336-1347.
4. Tracey I, Carr CA, Guimaraes AR, Worth JL, Navia BA, Gonzalez RG. Brain choline-containing compounds are elevated in HIV-positive patients before the onset of AIDS dementia complex: a proton magnetic resonance spectroscopic study. Neurology 1996;46:783-788.
5. Wu Y, Storey P, Cohen BA, Epstein LG, Edelman RR, Ragin AB. Diffusion alterations in corpus callosum of patients with HIV. AJNR Am J Neuroradiol 2006;27:656-660.
6. Chang L, Ernst T, Leonido-Yee M, et al. Highly active antiretroviral therapy reverses brain metabolite abnormalities in mild HIV dementia. Neurology 1999;53:782-789.
7. Chang L, Ernst T, St Hillaire C, Conant K. Antiretroviral treatment alters relationship between MCP-1 and neurometabolites in HIV patients. Antivir Ther 2004;9:431-440.
8. Chang L, Ernst T, Witt MD, Ames N, Gaiefsky M, Miller E. Relationships among brain metabolites, cognitive function, and viral loads in antiretroviral-naive HIV patients. Neuroimage 2002;17:1638-1648.
9. Chang L, Ernst T, Witt MD, et al. Persistent brain abnormalities in antiretroviral-naive HIV patients 3 months after HAART. Antivir Ther 2003;8:17-26.
10. Lentz MR, Lee V, Westmoreland SV, Ratai EM, Halpern EF, Gonzalez RG. Factor analysis reveals differences in brain metabolism in macaques with SIV/AIDS and those with SIV-induced encephalitis. NMR Biomed 2008;21:878-887.
11. Baer L. Factor analysis of symptom subtypes of obsessive compulsive disorder and their relation to personality and tic disorders. J Clin Psychiatry 1994;55(suppl):18-23.
12. Genser B, Cooper PJ, Yazdanbakhsh M, Barreto ML, Rodrigues LC. A guide to modern statistical analysis of immunological data. BMC Immunol 2007;8:27.
13. Byrne BM. Factor analytic models: viewing the structure of an assessment instrument from three perspectives. J Pers Assess 2005;85:17-32.
14. Lloyd DG, Golfis G, Knox AJ, Fayne D, Meegan MJ, Oprea T I. Oncology exploration: charting cancer medicinal chemistry space. Drug Discov Today 2006;11:149-159.
15. Hanley AJ, Karter AJ, Festa A, et al. Factor analysis of metabolic syndrome using directly measured insulin sensitivity: The Insulin Resistance Atherosclerosis Study. Diabetes 2002;51:2642-2647.
16. Dennis JL, Oien KA. Hunting the primary: novel strategies for defining the origin of tumours. J Pathol 2005;205:236-247.
17. Griffin JL. Metabolic profiles to define the genome: can we hear the phenotypes? Philos Trans R Soc Lond B Biol Sci 2004;359:857-871.
18. Confort-Gouny S, Vion-Dury J, Nicoli F, Dano P, Gastaut JL, Cozzone PJ. Metabolic characterization of neurological diseases by proton localized NMR spectroscopy of the human brain. C R Acad Sci III 1992;315:287-293.
19. Confort-Gouny S, Vion-Dury J, Nicoli F, et al. A multiparametric data analysis showing the potential of localized proton MR spectroscopy of the brain in the metabolic characterization of neurological diseases. J Neurol Sci 1993;118:123-133.
20. Salvan AM, Lamoureux S, Michel G, Confort-Gouny S, Cozzone PJ, Vion-Dury J. Localized proton magnetic resonance spectroscopy of the brain in children infected with human immunodeficiency virus with and without encephalopathy. Pediatr Res 1998;44:755-762.
21. Yiannoutsos CT, Ernst T, Chang L, et al. Regional patterns of brain metabolites in AIDS dementia complex. Neuroimage 2004;23:928-935.
22. Sacktor N, McDermott MP, Marder K, et al. HIV-associated cognitive impairment before and after the advent of combination therapy. J Neurovirol 2002;8:136-142.
23. Conant K, Garzino-Demo A, Nath A, et al. Induction of monocyte chemoattractant protein-1 in HIV-1 Tat-stimulated astrocytes and elevation in AIDS dementia. Proc Natl Acad Sci U S A 1998;95:3117-3121.
24. Duyn JH, Gillen J, Sobering G, van Zijl PC, Moonen CT. Multisection proton MR spectroscopic imaging of the brain. Radiology 1993;188:277-282.
25. Soher BJ, van Zijl PC, Duyn JH, Barker PB. Quantitative proton MR spectroscopic imaging of the human brain. Magn Reson Med 1996;35:356-363.
26. Kreis R, Ernst T, Ross BD. Absolute quantitation of water and metabolites in the human brain. II. Metabolite concentrations. J Magn Reson B 1993;102:9-19.
27. Kaiser HF. The varimax criterion for analytic rotation in factor analysis. Psychometrika 1958;23:187-200.
28. Coste J, Bouee S, Ecosse E, Leplege A, Pouchot J. Methodological issues in determining the dimensionality of composite health measures using principal component analysis: case illustration and suggestions for practice. Qual Life Res 2005;14:641-654.
29. Paul RH, Yiannoutsos CT, Miller EN, et al. Proton MRS and neuropsychological correlates in AIDS dementia complex: evidence of subcortical specificity. J Neuropsychiatry Clin Neurosci 2007;19:283-292.
30. Sacktor N, Skolasky RL, Ernst T, et al. A multicenter study of two magnetic resonance spectroscopy techniques in individuals with HIV dementia. J Magn Reson Imaging 2005;21:325-333.
31. Cinque P, Bestetti A, Marenzi R, et al. Cerebrospinal fluid interferon-gamma-inducible protein 10 (IP-10, CXCL10) in HIV-1 infection. J Neuroimmunol 2005;168:154-163.
32. Griffin DE, Wesselingh SL, McArthur JC. Elevated central nervous system prostaglandins in human immunodeficiency virus-associated dementia. Ann Neurol 1994;35:592-597.
33. Letendre SL, Lanier ER, McCutchan JA. Cerebrospinal fluid beta chemokine concentrations in neurocognitively impaired individuals infected with human immunodeficiency virus type 1. J Infect Dis 1999;180:310-319.
34. Sporer B, Kastenbauer S, Koedel U, Arendt G, Pfister HW. Increased intrathecal release of soluble fractalkine in HIV-infected patients. AIDS Res Hum Retroviruses 2003;19:111-116.
35. Meyerhoff DJ, Bloomer C, Cardenas V, Norman D, Weiner MW, Fein G. Elevated subcortical choline metabolites in cognitively and clinically asymptomatic HIV+ patients. Neurology 1999;52:995-1003.
36. Thompson PM, Dutton RA, Hayashi KM, et al. Thinning of the cerebral cortex visualized in HIV/AIDS reflects CD4+ T lymphocyte decline. Proc Natl Acad Sci U S A 2005;102:15647-15652.
37. Filippi CG, Sze G, Farber SJ, Shahmanesh M, Selwyn PA. Regression of HIV encephalopathy and basal ganglia signal intensity abnormality at MR imaging in patients with AIDS after the initiation of protease inhibitor therapy. Radiology 1998;206:491-498.
38. Sevigny JJ, Albert SM, McDermott MP, et al. Evaluation of HIV RNA and markers of immune activation as predictors of HIV-associated dementia. Neurology 2004;63:2084-2090.
39. Sevigny JJ, Albert SM, McDermott MP, et al. An evaluation of neurocognitive status and markers of immune activation as predictors of time to death in advanced HIV infection. Arch Neurol 2007;64:97-102.
40. Kaul M, Zheng J, Okamoto S, Gendelman HE, Lipton SA. HIV-1 infection and AIDS: consequences for the central nervous system. Cell Death Differ 2005;12(suppl 1):878-892.
41. Ryan LA, Zheng J, Brester M, et al. Plasma levels of soluble CD14 and tumor necrosis factor-alpha type II receptor correlate with cognitive dysfunction during human immunodeficiency virus type 1 infection. J Infect Dis 2001;184:699-706.
42. Ragin AB, Wu Y, Storey P, Cohen BA, Edelman RR, Epstein LG. Monocyte chemoattractant protein-1 correlates with subcortical brain injury in HIV infection. Neurology 2006;66:1255-1257.
43. Costello AB, Osborne JW. Best practices in exploratory factor analysis: four recommendations for getting the most from your analysis. Pract Assess Res Eval 2005;10:1-9.
44. Fabrigar LR, Wegener DT, MacCallum RC, Strahan EJ. Evalutating the use of exploratory factor analysis in psychological research. Psychol Methods 1999;4:272-299.
45. MacCallum RC, Widaman KF, Zhang SB, Hong SH. Sample size in factor analysis. Psychol Methods 1999;4:84-99.
46. Mulaik SA. Blurring the distinctions between component analysis and common factor-analysis. Multivariate Behav Res 1990;25:53-59.
47. Widaman KF. Common factor analysis versus principal component analysis: differential bias in representing model parameters? Multivariate Behav Res 1993;28:263-311.